Although knowledge of cancer biology in the laboratory has increased exponentially in recent years, progress in cancer treatment in the clinic has been more gradual. To accelerate progress in the clinic, a larger number of outstanding clinician-investigators is needed to perform patient-oriented, therapeutic translational research. The M. D. Anderson (MDACC) K12 Paul Calabresi Program in Clinical Oncology has taken advantage of an extraordinary environment for clinical and translational research to begin to fill this need. MDACC brings together 1,469 faculty and 29,500 new patients each year with a well-developed infrastructure for clinical and laboratory research and novel ideas that are supported by 254 NCI grants. For 6 decades, MDACC investigators have made important contributions to clinical cancer research. Since the inception of the MDACC K12 Program in 2000, 9 junior-faculty investigators have been trained in patient- based translational research with the program's support. Currently four faculty investigators and two fellows are being trained in this program. All nine of our graduates have become highly productive clinician- scientists, who have published 388 peer-reviewed papers, competed successfully for $10.9 M in grants and contracts and have headed 89 therapeutic protocols. The four faculty and two fellow trainees supported by this award will conduct hypothesis driven clinical trials, participate in a cancer-oriented K30 curriculum and can earn an M.S./Ph.D. in Patient-Based Biological Research. To maximize use of MDACC's extensive resources for clinical, translational and basic research, this combined K12 program will include fellows and junior faculty not only from MDACC but also from the Baylor College of Medicine. This program emphasizes individualized training plans that include didactic classes, clinical trials, laboratory research projects, publication of results, individualized training experiences, and long-range planning. Each Calabresi scholar is guided by a clinical mentor and a translational mentor as well as by the PI and the program's Advisory Committee, composed of experts in clinical, laboratory, and translational research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Physician Scientist Award (Program) (PSA) (K12)
Project #
5K12CA088084-14
Application #
8543534
Study Section
Special Emphasis Panel (ZCA1-RTRB-A (J))
Program Officer
Damico, Mark W
Project Start
2000-09-13
Project End
2015-08-31
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
14
Fiscal Year
2013
Total Cost
$650,081
Indirect Cost
$48,154
Name
University of Texas MD Anderson Cancer Center
Department
Miscellaneous
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Falchook, Gerald S; Moulder, Stacy; Naing, Aung et al. (2015) A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer. Invest New Drugs 33:177-86
Ding, Yao; Mohamed, Abdallah S R; Yang, Jinzhong et al. (2015) Prospective observer and software-based assessment of magnetic resonance imaging quality in head and neck cancer: Should standard positioning and immobilization be required for radiation therapy applications? Pract Radiat Oncol 5:e299-308
Falchook, Gerald S; Wheler, Jennifer J; Naing, Aung et al. (2015) Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors. Invest New Drugs 33:215-24
Falchook, Gerald; Kurzrock, Razelle; Gouw, Launce et al. (2014) Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study. Invest New Drugs 32:1181-7
Suraokar, M B; Nunez, M I; Diao, L et al. (2014) Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications. Ann Oncol 25:1184-92
Thomas, Ligy; Lai, Stephen Y; Dong, Wenli et al. (2014) Sorafenib in metastatic thyroid cancer: a systematic review. Oncologist 19:251-8
Chen, Guo; Chakravarti, Nitin; Aardalen, Kimberly et al. (2014) Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target. Clin Cancer Res 20:5537-46
Falchook, Gerald S; Lippman, Scott M; Bastida, Christel C et al. (2014) Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment. Head Neck 36:E25-7
Dadu, Ramona; Devine, Catherine; Hernandez, Mike et al. (2014) Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab 99:2086-94
Gold, Kathryn A; Kim, Edward S; Liu, Diane D et al. (2014) Prediction of survival in resected non-small cell lung cancer using a protein expression-based risk model: implications for personalized chemoprevention and therapy. Clin Cancer Res 20:1946-54

Showing the most recent 10 out of 106 publications